Swiss-based global healthcare company, Novartis, intends to separate its Sandoz business, a major global player in generic pharmaceuticals and biosimilars, by way of a publicly listed standalone 100% spin-off. Sandoz…
Swiss-based global healthcare company, Novartis, intends to separate its Sandoz business, a major global player in generic pharmaceuticals and biosimilars, by way of a publicly listed standalone 100% spin-off. Sandoz…
…
Rankings & Reports
M&A
Equity
Healthcare Investing Review
Healthcare Real Assets Report
Resources & Events
Resource Hub
Sector Events
Private Capital Conference
Real Assets Conference